Integer
Develops and manufactures cardiac, vascular, and neuromodulation devices for medical-technology companies.
Something off on this page? Send us feedback.
Profile
Develops and manufactures components, subassemblies, and finished devices for cardiac, vascular, and neuromodulation programs. Revenue comes largely from custom work for large medical-device OEMs, with roughly half tied to Abbott, Boston Scientific, and Medtronic.
Develops and manufactures medical-device components, subassemblies, and finished systems across three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation, and Other Markets. The portfolio spans catheters, guidewires, delivery systems, implantable batteries, capacitors, feedthroughs, leads, pulse generators, precision machining, and proprietary surface coatings.
Runs a manufacturing network across the United States, Mexico, Ireland, and several other countries, pairing customer-specific engineering with scaled production. Large medical-device OEMs contract most work to their specifications; Abbott, Boston Scientific, and Medtronic together account for roughly half of sales.
Programs depend on qualified suppliers, validated quality systems, and regulatory approvals, while finished-device facilities remain subject to FDA and international oversight. A pending KKR acquisition would take the shares private, subject to stockholder and regulatory approvals.
Company facts
Categories
Key statistics
Year to date +63.2% · Average volume (30d) 1.3M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | Benchmark | Downgrade | Buy | Hold | ||
| Aug 13, 2026 | Benchmark | Downgrade | Buy | Hold | ||
| Aug 4, 2026 | Truist Securities | Downgrade | Buy | Hold | ||
| Aug 4, 2026 | Freedom Capital Markets | Downgrade | Buy | Hold | ||
| Aug 4, 2026 | Oppenheimer | Downgrade | Outperform | Perform |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 3, 2026Q2 FY26 | $1.38 | $1.60 | +15.9% | $451.1M | $464.1M | +2.9% | +2.67% |
| Apr 30, 2026Q1 FY26 | $1.21 | $1.20 | −0.8% | $426.5M | $439.6M | +3.1% | −5.06% |
| Feb 19, 2026Q4 FY25 | $1.70 | $1.76 | +3.5% | $462.7M | $472.1M | +2.0% | +2.23% |
| Oct 23, 2025Q3 FY25 | $1.68 | $1.79 | +6.5% | $462.7M | $467.7M | +1.1% | −1.33% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $436.2M | $472.8M | $466.6M | $470.9M | $439.6M | $464.1M | |
| Gross profit | $105.9M | $107.3M | $108.3M | $106.1M | $109.6M | $112.9M | |
| Operating income | $51.7M | $52.7M | $53.6M | $51.1M | $35.2M | $34.5M | |
| Net income | −$22.5M | $37.0M | $39.7M | $48.6M | $16.5M | $23.6M | |
| Diluted EPS | −$0.66 | $1.04 | $1.11 | $1.38 | $0.48 | $0.69 | |
| Gross margin | 24.3% | 22.7% | 23.2% | 22.5% | 24.9% | 24.3% | |
| Operating margin | 11.8% | 11.1% | 11.5% | 10.9% | 8.0% | 7.4% |
Fiscal years (4-quarter sums)FY21 $1.22B · FY22 $1.38B · FY23 $1.58B · FY24 $1.72B · FY25 $1.85B
Revenue by product · Q2 FY26
Revenue by geography · FY25
Balance sheet, Jul 3, 2026Cash & short-term investments $21.4M · Total debt $1.36B · Total assets $3.42B · Shareholders' equity $1.72B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 33.95M · Float 33.52M · 98.7% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 5.35M | 15.77% | 13F | Aug 7, 2026 |
| Invesco Ltd. | 2.25M | 6.62% | 13F | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 2.04M | 6.01% | 13F | Aug 13, 2026 |
| Nomura Holdings Inc | 1.82M | 5.40% | 13G | Aug 14, 2026 |
| Dimensional Fund Advisors LP | 1.63M | 4.79% | 13F | Aug 11, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 13, 2026 | Tommy P. Thomas | officer: VP, Corporate Controller | −825 | $85.00 |
| Nov 11, 2025 | Tommy P. Thomas | officer: VP, Corporate Controller | −884 | $70.15 |
| Nov 12, 2025 | John A. Harris | officer: EVP, Global Ops and Manufactur | +1,650 | $70.00 |
| Nov 6, 2025 | Cheryl C. Capps | director | +1,600 | $66.70 |
| Nov 7, 2025 | Diron Smith | officer: EVP, Chief Financial Officer | +1,116 | $67.19 |
Peers
- TE Connectivity
Catheter, Nitinol, and polymer tubing competitor for interventional OEMs
- Jabil
Largest healthcare contract manufacturer with expanding catheter and EP programs
- Nordson
Proprietary catheter components supplier to the same interventional OEM base
- Flex
$2.6B Health Solutions contract manufacturer serving cardiac and neural OEMs
- Plexus
Full-device EMS CDMO serving cardiac and life sciences OEMs
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Integer | $125.33 | +0.01% | $4.26B | 34.2 | 18.8 | 2.3 | −2.6% |
| TE Connectivity | $202.66 | +0.01% | $58.76B | 19.9 | 16.1 | 3.1 | +13.8% |
| Jabil | $303.90 | +0.82% | $31.59B | 37.6 | 19.1 | 0.9 | +11.8% |
| Nordson | $324.59 | +0.01% | $18.09B | 32.8 | 25.8 | 6.1 | +10.3% |
| Flex | $110.65 | +0.15% | $40.82B | 42.7 | 21.2 | 1.4 | +20.6% |
| Plexus | $240.87 | +0.00% | $6.44B | 35.6 | 24.0 | 1.4 | +28.1% |
| Median | 35.6 | 21.2 | 1.4 | +13.8% |